Accessibility Menu
Equillium logo

Equillium(NASDAQ) EQ

Current Price$2.76
Market Cap$166.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-81%
5 Year-49%
1 Year+606%
1 Month-4%
Equillium last closing stock price
MetricPriceDate
Last closeUSD 2.762026-07-22
Equillium stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.34%USD 2.622026-07-15
1 month-3.5%USD 2.862026-06-22
3 month+27.19%USD 2.172026-04-23
Year to date+78.06%USD 1.552025-12-31
1 year+605.88%USD 0.392025-07-22
3 year+235.32%USD 0.822023-07-21
5 year-48.98%USD 5.412021-07-23
Since inception-81.21%USD 14.002018-10-12

Equillium Financials at a Glance

Market Cap

$166.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.06M

EPS (TTM)

-$0.32

P/E Ratio

-8.18

Dividend

$0.00

Beta (Volatility)

0.81 (Low)

Price

$2.76

Volume

32,469

Open

$2.64

Previous Close

$2.76

Daily Range

$2.52 - $2.79

52-Week Range

$0.36 - $3.54

Estimated Earnings Date

Aug 13, 2026

EQ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Equillium

Equillium develops medicines for people with severe immune system diseases. Its main products aim to help those with gut and autoimmune problems. These treatments target the body’s immune response to reduce harmful inflammation.

What’s in the Medicine Cabinet?

  • EQ504 (AhR modulator): Preclinical drug for gut diseases like ulcerative colitis; no revenue contribution.
  • EQ302 (IL-15/IL-21 inhibitor): Preclinical oral therapy for celiac and other gut diseases; no revenue contribution.
  • EQ101: Developed for skin lymphoma and hair loss; not actively developed; no revenue contribution.
  • EQ102: Developed for gut diseases; not actively developed; no revenue contribution.

Growth Spurts and Strategic Moves

  • Acquired Ariagen in October 2024 for rights to EQ504.
  • Bought Bioniz Therapeutics in February 2022 for EQ302 and related technology.
  • Ended partnership with Biocon in September 2025; all rights to itolizumab returned to Biocon.
  • Raised $30M in August 2025 and $35M in March 2026 through private placements to fund research.
  • All previous revenue came from a development deal with Ono Pharmaceutical, which ended in October 2024.

Why Equillium Stands Out (Without Standing on a Soapbox)

Equillium focuses on new ways to treat immune diseases without suppressing the whole immune system. Its pipeline uses targeted approaches, aiming to reduce side effects. The company relies on outside partners for manufacturing and has no commercial sales yet.

Five Things You Need to Know

  • Revenue was $0 in QQ3 2025, down 100% from $12M in QQ3 2024.
  • Net loss was $-5M in QQ3 2025, down 573.8% from QQ3 2024.
  • Research spending fell to $12.8M in 2025, down $24.6M from 2024.
  • Cash and equivalents were $30.3M at December 31, 2025, before a $35M raise in March 2026.
  • Full-time employees dropped to 13 by end of 2025, from 35 previously.

Bottom Line

Equillium shifted from partnership funding to developing its own pipeline. The company now focuses on early-stage drugs for immune diseases, with no product sales yet.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Bruce D. Steel, CFA, MBA

Website

www.equilliumbio.com

Headquarters

La Jolla, CA 92037, US

EQ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-61.43%

Return on Capital

-80.62%

Return on Assets

-30.21%

Earnings Yield

-12.22%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$166.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

63.23M

Volume

32.47K

Avg. Volume

802.71K

Financials (TTM)

Gross Profit

-$79.00K

Operating Income

-$20.38M

EBITDA

-$18.95M

Operating Cash Flow

-$18.88M

Capital Expenditure

-$47.00K

Free Cash Flow

-$18.93M

Cash & ST Invst.

$61.32M

Total Debt

$692.00K

Equillium Performance Analysis

Equillium annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 15,759,000N/A
20232023-12-31USD 36,084,000129.0%
20242024-12-31USD 41,095,00013.9%
20252025-12-31USD 0N/A
Equillium sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Equillium annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.8536.5%
20232023-12-31USD -0.38-79.3%
20242024-12-31USD -0.23-40.6%
20252025-12-31USD -0.3971.3%
Equillium sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.3%
Q32025-09-3025.0%
Q42025-12-3165.8%
Q12026-03-31-34.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$24.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$166.29MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.88M

N/A

Employees

14

N/A

Net Income

-$5.31M

+38.6%

EBITDA

-$5.29M

+38.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$61.32M

+322.9%

Total Debt

$692.00K

+134.6%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$251.00K

+68.5%

Short Term Debt

$441.00K

+202.1%

Return on Assets

-30.21%

N/A

Return on Invested Capital

-34.11%

N/A

Free Cash Flow

-$4.30M

+47.3%

Operating Cash Flow

-$4.30M

+47.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPSCCentury Therapeutics, Inc.
$2.15-4.02%
FBIOFortress Biotech, Inc.
$3.55+0.57%
CUECue Biopharma, Inc.
$34.20+2.21%
NRXPNRx Pharmaceuticals, Inc.
$4.48+0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$23.04+0.04%
ONDSOndas
$8.00+0.04%
SMCISuper Micro Computer
$30.56+0.20%
AALAmerican Airlines Group
$14.79-0.03%

Questions About EQ

What is the current price of Equillium?

Equillium is trading at $2.76 per share.

What is the 52-week range for Equillium?

Over the past 52 weeks, Equillium has traded between $0.36 and $3.54.

How much debt does Equillium have?

As of the most recent reporting period, Equillium reported total debt of $692.00K.

How much cash does Equillium have on hand?

Equillium reported $61.32M in cash and cash equivalents in its most recent financial results.

What is Equillium’s dividend yield?

Equillium does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services